Patents Assigned to ADVANCED REGEN MEDICAL TECHNOLOGIES, LLC
-
Patent number: 11286463Abstract: A method comprising (a) obtaining young adult stem cells (YASC) from a first subject; (b) lysing the YASC to generate a lysate comprising an intracellular matrix (ICM) and other cellular components; (c) filtering the lysate through a filter having a membrane size of equal to or less than 0.4 micron to obtain a filtrate; and (d) applying the filtrate to a culture of aged adult stem cells (AASC) for a time period ranging from about 24 hours to about 30 days to generate a reprogrammed AASC (R-AASC) wherein the AASC were obtained from a second subject and wherein the R-AASC when infused into a breast cancer stem model results in a reduced number of breast cancer cells in bone marrow in comparison to a breast cancer stem model having AASC that have not been reprogrammed.Type: GrantFiled: October 26, 2015Date of Patent: March 29, 2022Assignee: Advanced ReGen Medical Technologies, LLCInventors: Steven J. Greco, Vincent C. Giampapa
-
Patent number: 11219643Abstract: A method comprising obtaining a first cell sample from a first subject; obtaining a second cell sample from a second subject; culturing the first cell sample in the presence of at least a portion of a culture media of the second cell sample for a time period ranging from about 24 hours to about 6 weeks to produce a restoring composition; and contacting the restoring composition with the second cell sample for a period of time ranging from about 24 hours to about 6 weeks to produce a restored composition.Type: GrantFiled: August 24, 2018Date of Patent: January 11, 2022Assignee: Advanced Regen Medical Technologies, LLCInventor: Vincent C. Giampapa
-
Patent number: 11203754Abstract: A method comprising administering to a subject a composition comprising an isolated microRNA having a sequence selected from the group consisting of miR-19a-3p (SEQ ID NO:1); miR-103a-3p (SEQ ID NO:2); miR-106b-5p (SEQ ID NO:3); miR-146a-5p (SEQ ID NO:4); miR-223-5p (SEQ ID NO:5); miR-4497 (SEQ ID NO:6); miR-1303 (SEQ ID NO:7); miR-619-5p (SEQ ID NO:8); miR-1273f (SEQ ID NO:9); miR-7851-3p (SEQ ID NO:10); a functional variant thereof; and combinations thereof.Type: GrantFiled: April 28, 2017Date of Patent: December 21, 2021Assignee: Advanced ReGen Medical Technologies, LLCInventors: Steven John Greco, Pranela Rameshwar
-
Patent number: 10772911Abstract: A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.Type: GrantFiled: March 24, 2015Date of Patent: September 15, 2020Assignee: Advanced ReGen Medical Technologies, LLCInventors: Steven John Greco, Vincent C. Giampapa
-
Patent number: 10717981Abstract: Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.Type: GrantFiled: January 17, 2019Date of Patent: July 21, 2020Assignee: Advanced ReGen Medical Technologies, LLCInventors: Steven John Greco, Pranela Rameshwar, Khadidiatou Guiro, Seda Ayer
-
Patent number: 9994814Abstract: A method comprising obtaining a donor composition from a donor subject wherein the donor composition comprises a plurality of adult stem cell types; obtaining a receiver composition from a receiver subject wherein the receiver composition comprises a plurality of adult stem cell types; and co-culturing the donor composition and receiver composition wherein co-culturing comprises contacting the receiver composition a cell-free portion of the donor composition to produce a restored composition. Pharmaceutical compositions comprising a restored composition.Type: GrantFiled: April 9, 2014Date of Patent: June 12, 2018Assignee: Advanced Regen Medical Technologies, LLCInventor: Vincent C. Giampapa
-
Publication number: 20170173076Abstract: A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.Type: ApplicationFiled: March 24, 2015Publication date: June 22, 2017Applicant: Advanced ReGen Medical Technologies, LLCInventors: Steve GRECO, Vincent C. GIAMPAPA
-
Publication number: 20160145571Abstract: A method comprising obtaining a donor composition from a donor subject wherein the donor composition comprises a plurality of adult stem cell types; obtaining a receiver composition from a receiver subject wherein the receiver composition comprises a plurality of adult stem cell types; and co-culturing the donor composition and receiver composition wherein co-culturing comprises contacting the receiver composition a cell-free portion of the donor composition to produce a restored composition. Pharmaceutical compositions comprising a restored composition.Type: ApplicationFiled: April 9, 2014Publication date: May 26, 2016Applicant: Advanced Regen Medical Technologies, LLCInventor: Vincent C. Giampapa
-
Publication number: 20160108370Abstract: A method comprising (a) obtaining young adult stem cells (YASC) from a first subject; (b) lysing the YASC to generate a lysate comprising an intracellular matrix (ICM) and other cellular components; (c) filtering the lysate through a filter having a membrane size of equal to or less than 0.4 micron to obtain a filtrate; and (d) applying the filtrate to a culture of aged adult stem cells (AASC) for a time period ranging from about 24 hours to about 30 days to generate a reprogrammed AASC (R-AASC) wherein the AASC were obtained from a second subject and wherein the R-AASC when infused into a breast cancer stem model results in a reduced number of breast cancer cells in bone marrow in comparison to a breast cancer stem model having AASC that have not been reprogrammed.Type: ApplicationFiled: October 26, 2015Publication date: April 21, 2016Applicant: ADVANCED REGEN MEDICAL TECHNOLOGIES, LLCInventors: Steven J. Greco, Vincent C. Giampapa